sFig. 1



sFig. 1 Flowchart of patient selection.

sFig.2



sFig.2 Risk factors of HBV recurrence after LT

sTable 1

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplementary table 1 Performance of baseline qHBsAg and qHBcAb level in predicting HBsAg clearance in LT cohorts | | | | | | | | |
|  |  |  |  |  |  |  |  |  |
| Cohorts | cutoff value | AUROC | Sensitivity | Specificity | +LR | -LR | +PV | -PV |
| qHBsAg | ≤2.82 log10 IU/mL | 0.687 | 51.85 | 76.32 | 2.19 | 0.63 | 75.70 | 52.70 |
| qHBcAb | ≥4.25 log10 IU/mL | 0.651 | 80.00 | 56.10 | 1.82 | 0.36 | 69.00 | 69.70 |
| Combined qHBsAg | qHBcAb≥3.68 log10 IU/mL | 0.727 | 72.00 | 62.16 | 1.90 | 0.45 | 72.00 | 62.20 |
| with qHBcAb | qHBsAg≤1.81log10 IU/mL |

AUROC, area under the receiver operator characteristic curve; −LR, negative likelihood ratio; +LR, positive likelihood ratio; −PV, negative

predictive value; +PV, positive predictive value

sTable 2

Biomarker characteristics of donor at baseline

|  |  |  |  |
| --- | --- | --- | --- |
| Biomarker Characteristics of Donor | HBsAg recurrence | Sustained HBsAg loss | *p* |
| in follow-up time | after LT |
| (n=37) | (n=42) |
| HBcAb (positive%) | 14 (37.8%) | 16 (38.1%) | *ns* |
|  |  |  |  |
| HBsAb (positive%) | 15 (40.5%) | 22 (52.4%) | *ns* |
|  |  |  |  |
| HBsAg (positive%) | 0 (0%) | 0 (0%) | *ns* |
|  |  |  |  |

ns: no significant